US EditionSGLT2 Inhibitors Linked to Breast Cancer Outcomes
Summary by BIOENGINEER.ORG
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Scienmag: Latest Science and Health NewsReposted by 
BIOENGINEER.ORG
BIOENGINEER.ORGSGLT2 Inhibitors Linked to Breast Cancer Outcomes
In a groundbreaking systematic review and meta-analysis recently published in BMC Cancer, researchers have shed new light on the complex relationship between sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and breast cancer outcomes. SGLT-2 inhibitors, primarily known for their glucose-lowering efficacy in type 2 diabetes, have emerged as potential modulators of cancer prognosis. This comprehensive analysis compares the impact of SGLT-2 inhi…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
